Liver involvement in cystic fibrosis

Journal of Hepatology

Volumn 31, Issue 5, 1999, Pages 946-954

  Colombo, Carla ^a   Crosignani, Andrea ^b   Battezzati, Pier Maria ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AUTOSOMAL RECESSIVE INHERITANCE; BILE SECRETION; CAUCASIAN; CAUSE OF DEATH; CHROMOSOME 7; CLINICAL FEATURE; CYSTIC FIBROSIS; EPITHELIUM; GENE MUTATION; ION TRANSPORT; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

EID: 0032718802     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80299-2     Document Type: Review

References (96)

1. Welsh MJ, Tsui L, Boat TF, Beaudet AL. Cystic fibrosis. Scriver CR, Beaudet AL, Sly WS, et al. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. 1995;3799-3876 McGraw-Hill, New York.
2. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 122:1993;1-9.
3. FitzSimmons SC. Cystic Fibrosis Foundation, Patient Registry 1996 Annual Data Report, Bethesda, Maryland. August 1997.
4. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 245:1989;1066-1073.
5. Bear CF, Li CH, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 68:1992;809-818.
6. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science. 256:1992;774-779.
7. Stutts MJ, Boucher RC. Cystic fibrosis gene and functions of CFTR. Implications of dysfunctional ion transport for pulmonary pathogenesis. Yankaskas JR, Knowles MR. Cystic Fibrosis in Adults. 1999;3-25 Lippincott-Raven Publishers, Philadelphia.
8. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, Kirk KL. Regulation of plasma membrane recycling by CFTR. Science. 256:1992;530-532.
9. Kazazian HH Jr. Population variation of common cystic fibrosis mutations: the Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat. 4:1994;167-177.
10. Tsui LC. The spectrum of cystic fibrosis mutations. Trends Genet. 8:1992;392-398.
11. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73:1993;251-254.
12. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui L-C, et al. Genetic determination of exocrine pancreatic function in Cystic Fibrosis. Am J Hum Genet. 50:1992;1178-1184.
13. Durie PR. Pancreatitis and mutations of the cystic fibrosis gene. N Engl J Med. 339:1998;687-688.
14. Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol. 22:1996;387-395.
15. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 105:1993;1857-1864.
16. Grubman SA, Fang SL, Mulberg AE, Perrone RD, Rogers LC, Lee DW, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology. 108:1995;584-592.
17. Strazzabosco M, Zsembery A, Fabris L. Electrolyte transport in bile ductular epithelial cells. J Hepatol. 24:(suppl.1):1996;78-87.
18. Grubman SA, Perrone RD, Lee DW, Bret MD, Jiang C, Cheng SH, et al. Regulation of chloride/bicarbonate exchanger activity by wild-type and mutant CFTR. [abstract] Pediatr Pulmonol Suppl. 14:1997;277-278.
19. Bhaskar KR, Turner BS, Grubman SA, Jefferson DM, LaMont JT. Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (Delta-f508) cystic fibrosis transmembrane regulator. Hepatology. 27:1998;54-61.
20. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr. 86:1975;683-689.
21. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 15:1992;677-684.
22. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology. 23:1996;281-287.
23. Lindblad A, Hultcrantz R, Strandvik B. Bile duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology. 16:1992;372-381.
24. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. [editorial] Gastroenterology. 104:1993;1865-1870.
25. Sokol RJ. Fat-soluble vitamins and their importance in patients who have cholestatic liver disease. Gastroenterol Clin North Am. 23:1994;673-705.
26. Malizia G, Brunt EM, Peters MG, Rizzo A, Broekelmann TJ, McDonald JA. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology. 108:1995;145-156.
27. McGill JM, Basavappa S, Fitz JG. Characterization of high conductance anion channels in rat bile duct epithelial cells. Am J Physiol. 262:1992;G703-G710.
28. Ferrari M, Colombo C, Sebastio G, Castiglione O, Quattrucci S, Dalla Piccola B, et al. Cystic fibrosis patients with liver disease are not genetically distinct. [letter] Am J Hum Genet. 48:1991;815-816.
29. Duthie A, Doherty DG, Williams C, Scott-Jupp R, Waener JO, Tanner MS, et al. Genotype analysis for DF 508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without liver disease. Hepatology. 15:1992;660-664.
30. Kovesi T, Corey M, Tsui L-C, Levison H, Durie P. The association between liver disease and mutations of the cystic fibrosis gene. [abstract] Pediatr Pulmonol. (Suppl 8):1992;244. 36.
31. Mack DR, Traystman MD, Colombo JL, Sammut PH, Kaufman SS, Vanderhoof JA, et al. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr. 127:1995;881-887.
32. Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, et al. Analysis of risk factors for the development of liver disease in CF. J Pediatr. 124:1994;393-399.
33. Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M, et al. Clinical and genetic risk factors for CF-related liver disease. Pediatrics. 103:1999;52-57.
34. Gaskin KJ, Waters DLM, Howman-Giles R, et al. Liver disease and common bile-duct stenosis in cystic fibrosis. N Engl J Med. 318:1988;340-346.
35. Nagel RA, Westaby D, Javaid A, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet. 2:1989;1422-1425.
36. Weber AM, Lenaerts C, Smith L, Roy CC. Screening and diagnosis of cystic fibrosis-related liver disease. Pediatr Pulmonol. (Suppl 4):1989;40-41.
37. O'Brien S, Keogan M, Casey M, Duffy G, McErlean D, Fitzgerald MX, et al. Biliary complications of cystic fibrosis. Gut. 33:1992;387-391.
38. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 66:1991;698-701.
39. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis. Therapeutic implications and long-term follow-up. Arch Dis Child. 68:1993;653-657.
40. Colombo C, Battezzati PM, Podda M. Hepatobiliary disease in cystic fibrosis. Semin Liver Dis. 14:1994;259-269.
41. Vawter GF, Shwachman H. Cystic fibrosis in adults: an autopsy study. Pathol Ann. 14:1979;357-382.
42. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 28:1999;S1-S13.
43. Lindblad A, Glaumann H, Strandvik B. CF-associated liver disease - a prospective study for 15 years. [abstract] Proceedings of the 22nd European Cystic Fibrosis Conference, Berlin. June 1998;109.
44. Colombo C, Battezzati PM, Strazzabosco M, Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis. 18:1998;227-235.
45. Maurage C, Lenaerts C, Weber AM, Brochu P, Yousef I, Roy CC. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr. 9:1989;17-20.
46. Bacon BR, Farahvash MJ, Janney CG, Neushwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 107:1994;1103-1109.
47. Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child. 72:1995;281-284.
48. Debray D, Lykavieris P, Gauthier F, Dousset B, Sardet A, Munck A, et al. Outcome of cystic fibrosis-associated liver cirrhosis. Management of portal hypertension. J Hepatol. 31:1999;77-83.
49. O'Brien S, Keogan M, Casey M, et al. Biliary complications of cystic fibrosis. Gut. 33:1992;387-391.
50. Westaby D. Liver and biliary disease in cystic fibrosis. Hodson ME, Gadders DM. Cystic Fibrosis. 1995;281-293 Chapman & Hall, London.
51. McGill JM, Williams DM, Hunt CM. Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig Dis Sci. 41:1996;540-542.
52. Stern RC, Rothstein FC, Doershuk CF. Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 5:1986;35-40.
53. Angelico M, Gandin C, Canuzzi P, Bertasi S, Cantafora A, De Santis A, et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology. 14:1991;768-775.
54. Colombo C, Bertolini E, Assaisso M, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr Scand. 82:1993;562-565.
55. Weber AM, Roy CC. Bile acid metabolism in children with cystic fibrosis. Acta Paediatr Scand. (Suppl 317):1985;9-15.
56. Strandvik B, Samuelson K. Fasting serum bile acid levels in relation to liver histopathology in cystic fibrosis. Scand J Gastroenterol. 20:1985;381-384.
57. Rattenbury JM, Taylor CJ, Health PK, Howie AF, Beckett GJ. Serum glutathione S-transferase B1 activity as an index of liver function in cystic fibrosis. J Clin Pathol. 48:1995;771-774.
58. Gerling B, Becker M, Staab D, Schuppan D. Prediction of liver disease according to serum collagen VI level in children with cystic fibrosis. N Engl J Med. 336:1997;1611-1612.
59. Leonardi S, Giambusso F, Sciuto C, Castiglione S, Castiglione N, La Rosa M. Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis? J Pediatr Gastroenterol Nutr. 27:1998;603-605.
60. Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of CF-associated hepatobiliary disease be predicted by clinical criteria? J Pediatr Gastroenterol Nutr. 25:1997;32-36.
61. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology. 14:1991;504-510.
62. Williams SGJ, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol. 22:1995;513-521.
63. Soto JA, Barish MA, Yucel EK, Siegenberg D, Ferrucci JT, Chuttani R. Magnetic resonance cholangiography: comparison with endoscopic retrograde cholangiopancreatography. Gastroenterology. 110:1996;589-597.
64. Williams S, Westaby D. New imaging techniques for the liver and biliary tree in cystic fibrosis. Proceedings of the 21st European Cystic Fibrosis Conference (EWGCF). 1997;48-50 Davos, Switzerland.
65. Delaney SJ, Wainwright BJ. New pharmaceutical approaches to the treatment of cystic fibrosis. Nat Med. 2:1996;392-393.
66. Yang Y, Raper SE, Cohn JA, Engelhardt JF, Wilson JM. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci. 90:1993;4601-4605.
67. Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr. 24:1997;573-589.
68. Poupon RE, Poupon R, Balkau B. Ursodiol for long-term treatment of primary biliary cirrhosis. New Engl J Med. 330:1994;1342-1347.
69. Crosignani A, Setchell KDR, Invernizzi P, Larghi A, Rodrigues CMP, Podda M. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 30:1996;333-358.
70. Beuer U, Kullak-Ublick GA, Paumgartner G. Mechanism of action of UDCA in cholestatic syndromes. Alvaro A, Benedetti B, Strazzabosco M. Vanishing Bile Duct Syndrome: Patyufangwahophysiology and Treatment. 1997;230-239 Kluwer Academic Publishers, Dordrecht.
71. 2+ mechanisms defective in cholestasis. J Clin Invest. 2:1993;984-993.
72. Shimokura GH, McGill M, Fitz JG. Ursodeoxycholate activates ion permeabilities in biliary epithelial cells. Gastroenterology. 107:1994;236-243.
73. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis. Effect of ursodeoxycholic acid. Hepatology. 11:1990;12-15.
74. Colombo C, Setchell KDR, Podda M, Crosignani A, Roda A, Curcio L, et al. The effects of ursodeoxycholic acid therapy in liver disease associated with cystic fibrosis. J Pediatr. 117:1990;482-489.
75. Cotting J, Lentze M, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 31:1990;918-921.
76. Galabert C, Montet JC, Lengrand D, Lecuire A, Sotta C, Figarella C, et al. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr. 121:1992;138-141.
77. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis. Hepatology. 23:1998;166-174.
78. Lepage G, Paradis K, Lacaille F, Sénéchal L, Ronco N, Champagne J, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr. 130:1997;52-58.
79. Dodge JA, Custance JM, Goodchild MC, Laing SC, Vaughan M. Paradoxical effects of essential fatty acid supplementation on lipid profiles and sweat electrolytes in cystic fibrosis. Br J Nutr. 63:1990;259-271.
80. Bittner P, Posselt HG, Sailer T, Ott H, Magdorf K, Wahn U, et al. The effect of treatment with ursodeoxycholic acid in cystic fibrosis and hepatopathy: results of a placebo-controlled study. Paumgartner G, Stiehl A, Gerok W. Bile Acids as Therapeutic Agents - From Basic Science to Clinical Practice. 1991;345-348 Kluwer Academic Publishers, Lancaster, UK.
81. O'Brien S, Fitzgerald MX, Hegarty JE. A controlled trial of ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatology. 4:1992;857-863.
82. Merli M, Bertasi S, Servi R, Diamanti S, Martino F, De Santis A, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr. 19:1994;198-203.
83. Colombo C, Battezzati PM, Podda M, Bettinardi, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology. 23:1996;1484-1490.
84. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid in cystic fibrosis-related liver disease. (Cochrane CF Group) J R Soc Med. 90:(S31):1997;6-12.
85. Colombo C, Crosignani A, Battezzati PM, Castellani R, Comi S, Melzi ML, et al. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with UDCA in patients with cystic fibrosis-associated liver disease. J Hepatol. 31:1999;672-677.
86. Colombo C, Crosignani A, Assaisso ML, Battezzati PM, Podda M, Giunta A, et al. Ursodeoxycholic acid therapy in cystic fibrosis associated liver disease: a dose-response study. Hepatology. 16:1992;924-930.
87. Colombo C, Roda A, Roda E, Piceni Sereni L, Maspero D, Giunta A, et al. Evaluation of an ursodeoxycholic acid oral load in the assessment of bile acid malabsorption in cystic fibrosis. Dig Dis Sci. 28:1983;306-311.
88. Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology. 102:1992;810-815.
89. Thompson GN. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis. J Pediatr Gastroenterol Nutr. 7:1988;214-217.
90. Sanyal AJ, Purdum PP, Luketic VA, Shiffman ML. Bleeding gastroesophageal varices. Semin Liver Dis. 13:1993;328-342.
91. Schuster SR, Shwachman H, Toyama WM, Rubino A, Taik-Khaw K. The management of portal hypertension in cystic fibrosis. J Pediatr Surg. 12:1977;201-206.
92. Berger KJ, Schreiber RA, Tchervenkov J, Kopelman H, Brassard R, Stein L. Decompression of portal hypertension in a child with cystic fibrosis after transjugular intrahepatic portosystemic stentshunt placement. J Pediatr Gastroenterol Nutr. 19:1994;322-325.
93. Louis D, Chazalette JP. Cystic fibrosis and portal hypertension. Interest of partial splenectomy. Eur J Pediatr Surg. 3:1993;22-24.
94. Stringer MD, Price JF, Mowat AP, Howard ER. Liver cirrhosis in cystic fibrosis. [letter] Arch Dis Child. 69:1993;407.
95. Noble-Jamieson G, Barnes ND, Jamieson N, Friend P, Caine R. Liver transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med. 89:(Suppl.27):1996;31-37.
96. Cooney GF, Fiel SB, Shaw LM, Cavarochi NC. Cyclosporin bioavailability in heart-lung transplantation candidates with cystic fibrosis. Transplantation. 49:1990;821-823.